Novel virus packaging plasmid and application thereof
By designing a novel recombinant adeno-associated virus (AAV) packaging plasmid pRH85-Cap921 and a multi-step purification method, the challenges of recombinant AAV yield and quality were solved, achieving efficient production of high-quality recombinant AAV suitable for multiple serotypes.
Patent Information
- Application Number
- CN202411451265.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-17
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-10-17
AI Technical Summary
Existing technologies struggle to efficiently produce high-quality recombinant adeno-associated virus, especially under high-dose administration, where virus yield and quality present significant challenges.
A novel recombinant adeno-associated virus packaging plasmid pRH85-Cap921 was designed, containing a specific nucleic acid sequence and Cap gene structure. Virus packaging was performed by co-transfection of HEK293T cells with three plasmids, and a multi-step purification method was used to improve virus yield and quality.
It significantly increased the yield of recombinant adeno-associated virus, reaching more than 2.5 times that of commonly used plasmids on the market, while maintaining the proportion of viral capsid proteins and infectivity, and is suitable for the production of multiple serotypes of the virus.
Smart Images

Figure CN118956906A_ABST
Abstract
Description
Technical Field
[0001] This disclosure belongs to the field of biotechnology, and in particular relates to a novel viral packaging plasmid and its application. Background Art
[0002] Adeno-associated virus (AAV) has achieved great success in clinical practice as a vector for gene therapy. In recent years, AAV-based gene therapy drugs such as Luxturna, Zolgensma, Hemgenix, Elevidys, and Roctavian have been approved for marketing, covering disease areas including ophthalmology, neurology, and hematology. Among these, except for Luxturna, which treats congenital amaurosis, the other five approved drugs require high doses (2 × 10⁻⁶). 13 Up to 1.3 × 10 14 (vg / kg) is administered systemically via intravenous injection. For adult patients, a single dose may be ~10 g / kg. 16 This will pose a significant challenge to virus production. Therefore, maximizing both the yield and quality of the virus is a goal that every gene therapy drug development company is striving for. Summary of the Invention
[0003] This disclosure provides a nucleic acid sequence, wherein the sequence comprises a first sequence, a second sequence, and a third sequence sequentially from the 5' end to the 3' end.
[0004] In some embodiments, the first sequence is as shown in SEQ ID NO: 13, the second sequence is as shown in SEQ ID NO: 15, and the third sequence is as shown in SEQ ID NO: 17.
[0005] In some implementations, the nucleic acid sequence is as shown in SEQ ID NO: 18.
[0006] In some implementations, the first sequence, the second sequence, and the third sequence are directly connected or connected by a connecting sequence.
[0007] Furthermore, this disclosure provides the use of the aforementioned nucleic acid sequence in enhancing Cap gene expression.
[0008] In some embodiments, the Cap gene serotype is selected from AAV9, 8, 1, 2, 3, 3B, 4, 5, 6, 7, 10, 11, 12, 13, rh10, or hu37.
[0009] In some embodiments, the recombinant adeno-associated virus packaging plasmid comprises a Rep gene and a Cap gene, wherein the 5' end of the Cap gene contains the nucleic acid sequence as described above.
[0010] In some embodiments, the nucleic acid sequence of the recombinant gland-associated packaging plasmid is as shown in any of SEQ ID NO: 2-4.
[0011] This disclosure also provides a recombinant adeno-associated virus vector system, characterized in that it comprises the recombinant adeno-associated virus packaging plasmid, the recombinant adeno-associated virus core plasmid, and the recombinant adeno-associated virus element helper plasmid as described above.
[0012] This disclosure also provides a recombinant adeno-associated virus particle, characterized in that it is obtained by co-transfecting a packaging cell line with a recombinant adeno-associated virus packaging plasmid, a recombinant adeno-associated virus core plasmid, and a recombinant adeno-associated virus element helper plasmid as described above.
[0013] Furthermore, this disclosure provides the use of the recombinant adeno-associated virus packaging plasmid as described above in the preparation of recombinant adeno-associated virus. Attached Figure Description
[0014] This disclosure can be more fully understood with reference to the following figures.
[0015] Figure 1 The structure of the plasmid is shown.
[0016] Figure 2 The virus titer detection is shown.
[0017] Figure 3 A gel image of the outer shell protein of the pEXG100-030RK and pRH85-Cap921 viral packages is shown.
[0018] Figure 4 The yields of AAV2 and AAV8 are shown. Detailed Implementation
[0019] The following description of this disclosure is merely intended to illustrate various embodiments of the disclosure. Therefore, the specific modifications discussed should not be construed as limiting the scope of this disclosure. It will be apparent to those skilled in the art that various equivalents, changes, and modifications can be made without departing from the scope of this disclosure, and it should be understood that these equivalent embodiments are included herein. All references cited herein, including publications, patents, and patent applications, are incorporated herein by reference in their entirety.
[0020] To enable those skilled in the art to better understand the present disclosure, the technical solutions in the embodiments of the present disclosure will be clearly and completely described below. Obviously, the described embodiments are only some embodiments of the present disclosure, and not all embodiments.
[0021] The experimental materials and primers used in this invention are shown in Table 1 and Table 2, respectively.
[0022] Table 1. Experimental Materials
[0023] Table 2. Primer Information
[0024] Example Example 1: Construction of recombinant adeno-associated virus packaging plasmid (1) Design and synthesis of the carrier, such as Figure 1 As shown, the AAV9 packaging plasmid pRH85-Cap921 was designed, and its specific sequence is shown in Table 3. A nucleic acid sequence was inserted before the Cap9 gene, which includes a truncated Rep8 sequence, a truncated Rep5 sequence, and a truncated Rep2 sequence, as detailed in Table 2. In some specific embodiments, the recombinant gland-associated packaging plasmid contains the following structure: Rep2 gene sequence - Cap truncated sequence - bGH pA - Rep8 truncated sequence - Rep5 truncated sequence - Rep2 truncated sequence - Cap gene sequence.
[0025] Table 3. Sequence List
[0026] Example 2: Preparation of recombinant adeno-associated virus (1) Packaging of the virus In our laboratory, we used a three-plasmid co-transfection system to package the virus into adherent HEK293T cells, namely pHelper plasmid (pEXG100-005HK, SEQ ID NO: 7), RepCap plasmid (pEXG100-030RK (SEQ ID NO: 1), pRH85-Cap921 (SEQ ID NO: 2)), and GOI plasmid (pEXG100-042GK, SEQ ID NO: 8), as shown in Table 4.
[0027] a) Cell seeding: 24 hours before transfection, the cells are plated and observed before transfection. The cells are in good condition and free from contamination when the cell density is 70%~80%. b) Prepare the plasmid-PEI transfection complex with a mass ratio of plasmid:PEI = 1:1. Add the pHelper plasmid, RepCap plasmid, and GOI plasmid (molar ratio 1:1:0.3) as shown in Table 4 to each well of a six-well plate with a total plasmid amount of 2.1 μg. After preparing 0.8 ml of the transfection complex, let it stand for 15 min. c) Transfection was performed using a transfection complex:serum-containing medium ratio of 1:10. The transfection complex was added dropwise to the cells to be transfected. d) Incubate for 72 hours and harvest the virus.
[0028] Table 4. Three-plasmid system
[0029] (2) Virus titer detection a) Sample information is shown in Table 5: Table 5. Sample Information
[0030] b) Prepare the Denase I treatment system according to Table 6: Table 6. Dnase I treatment system
[0031] Pre-dilute the sample to 1E+09 vg / ml to 4E+10 vg / ml, then take 40 μL of the DNase mixture and add 5 μL of sample to each tube. Incubate the sample at 37°C for 30 min, then add 5 μL of 50 mM EDTA solution to stop the reaction.
[0032] c) Preparation of SSDB: 10 mM Tris-HCl, pH 8.0, containing 2 μg / ml salmon sperm DNA (Invitrogen AM9680), 0.1% F-68.
[0033] Prepare the diluent (SSDB) according to Table 7: Table 7. Diluent (SSDB) Formulation
[0034] The DNase I-treated sample was diluted 1:10, i.e., (20 μL sample + 180 μL SSDB). d) Dilute the DNase I treated sample 1:10, i.e. (20 μL sample + 180 μL SSDB) e) Prepare the PCR system according to Table 8. Table 8. PCR reaction system
[0035] PCR reaction system: 22.4 µL PCR mix + 2.5 µL template = 24.9 µL.
[0036] f) Setting up the reaction program The PCR reaction procedure is shown in Table 9: Table 9. PCR reaction procedure
[0037] The PCR instrument's heating rate should be between 2.5℃ / s, and the reaction volume of the PCR instrument should be set to 40 μL.
[0038] g) Statistical analysis of the data is shown in Table 10. Table 10. Statistical Analysis of Data
[0039] The results showed that three independent experiments revealed that the newly designed pRH85-Cap921 packaged AAV9-100-042GK virus (pRH85-Cap921) yielded approximately 2.5 times higher yields than the commonly used AAV9-100-042GK (pEXG100-030RK) packaged AAV9-100-042GK. (See [link to relevant documentation]). Figure 2 .
[0040] Example 3: Production and purification of the virus After small-scale viral packaging, we determined that the AAV9 yield of the designed pRH85-Cap921 package was higher than that of pEXG100-030RK. Therefore, our next step was to use these two plasmids to produce a batch of virus to compare viral activity and the proportion of viral capsid proteins. (1) Packaging of the virus a) Cell seeding: 24 hours before transfection, the cells are plated and observed before transfection. The cells are in good condition and free from contamination when the cell density is 70%~80%. b) Prepare plasmid-PEI transfection complex: The mass ratio of plasmid:PEI is 1:1. With a total amount of 58 μg of plasmid in each 150 mm cell culture dish, add pHelper plasmid, RepCap plasmid and GOI plasmid (molar ratio 1:1:0.3) to prepare 10 ml of transfection complex and let it stand for 15 min. c) Transfection was performed using a transfection complex: serum-containing medium = 1:10. The transfection complex was added dropwise to a 150 mm cell culture dish to complete the transfection. d) Incubate for 72 hours and harvest the virus.
[0041] (2) Virus purification a) Use a sterile cell scraper to scrape cells from a 150 mm cell culture dish, centrifuge at 1500 g for 5 min at room temperature to obtain virus supernatant and cell pellet; b) Cell pellet was resuspended in TMS buffer (50 ml 1 M Tris-HCl pH 8, 30 ml 5 M NaCl, 2 ml 1 M MgCl2, and brought to a final volume of 1000 mL with sterile ddH2O), and 10% Triton X-100 was added to a final concentration of 0.4%. Viral supernatant was added to 1 / 4 volume of 5 x PEG8000 (400 g PEG-8000, 146 g NaCl, and brought to a final volume of 1000 mL with ddH2O) and incubated on ice for 2 h. c) After the virus supernatant was placed on ice, centrifuged at 4000 g for 30 min at 4℃, discarded the supernatant, and the virus particles were resuspended in PBS buffer. d) Mix the virus particle resuspension into the cell pellet resuspension, add 250 KU / ml of Benzonase to a final concentration of 25 U / ml, and place in an air shaker at 220 rpm and 37°C for 120 min; e) Add 25% sodium deoxycholate at a ratio of 1:50, treat in a 37°C water bath shaker for 30 min, centrifuge at 10000 g for 4°C for 10 min, and collect the supernatant; f) Add 5 M NaCl to a final concentration of 250 mM, and vortex at 500 rpm for 30 min to mix thoroughly. g) Use iodixanol gradients of 15%, 25%, 40% and 60% for ultracentrifugation, and take 40% of the virus layer; h) Dilute the virus solution 20-fold with buffer C (PBS + 0.005% F68) and filter it with a 0.45 μm syringe filter to remove impurities; The virus solution was concentrated using a 100 kDa ultrafiltration tube, the buffer was replaced with buffer C, and the solution was filtered using a 0.22 μm syringe filter to obtain the final virus solution, which was then retained for testing.
[0042] (3) The results of virus titer detection are shown in Table 11. Table 11. Virus titer detection results
[0043] (4) Detection of the proportion of the virus shell.
[0044] The modified system is prepared as shown in Table 12: Table 12. Configuration of the variant system
[0045] a) Denaturation: The prepared blank control and virus sample were heated at 75°C for 10 min to denature.
[0046] b) Prepare 1× electrophoresis buffer: Take 50 ml of NuPAGE MES SDS 20× electrophoresis buffer, add it to 950 ml of purified water, and mix well. Load the treated NuPAGE 4-12%BT Gel into a vertical electrophoresis tank.
[0047] c) Spotting: Take 10 μl of the denatured blank control, the virus sample, and 10 μl of Unstained Protein Marker, and add them to the sample wells respectively.
[0048] d) Electrophoresis: Turn on the power of the electrophoresis apparatus, set the voltage to 180 V and the time to 50 min.
[0049] e) Preparation of fixative: Prepare a fixative using ultrapure water with a ratio of 50% methanol and 7% acetic acid.
[0050] f) Gel stripping: After electrophoresis, turn off the power, remove the gel, place the gel in a container containing purified water, rinse and then discard the purified water.
[0051] g) Gel fixation: Add 50 rpm fixative to a container containing gel, place it on a track-type shaker, run it at 70 rpm for 30 min, and repeat once.
[0052] h) Staining: Discard the fixative, add 60 ml of SYPRO Ruby protein gel stain, place on a track-type shaker, and run overnight at 70 rpm.
[0053] i) Rinsing: Pour out the staining solution, gently rinse the gel with 100 ml of purified water, and discard the purified water.
[0054] j) Preparation of washing solution: Prepare washing solution with ultrapure water at a ratio of 10% methanol and 7% acetic acid.
[0055] k) Washing: Add 100 ml of washing solution to the container, place it on a track-type shaker, and run it at 70 rpm for 30 minutes.
[0056] l) Rinsing: Pour out the washing solution, gently rinse the gel with purified water, discard the purified water, and then add purified water to preserve the gel.
[0057] The results are shown below. Figure 3 Visually, the ratio of capsid proteins in both pEXG100-030RK and pRH85-Cap921 viral packages is consistent, close to VP1:VP2:VP3=1:1:10, indicating that the newly designed pRH85-Cap921 has no effect on the ratio of viral capsid proteins.
[0058] Example 4: Detection of viral infectivity (TCID50) This experiment involved serially diluting rAAV-GOI samples with known DNase I resistance (DRP) titers (i.e., physical titers) but unknown infection titers. These samples were then co-infected with saturated concentrations of Ad5 (ATCC number VR-1516) in 96-well plates to infect HeLaRC32 cells (HeLa cells expressing AAV2Rep and Cap, ATCC number CRL-2972). Infected cells were cultured at 37°C for 72 h. Cells in each well were lysed, and small amounts of lysate were analyzed by real-time quantitative PCR (qPCR). The vector amount was calculated based on the Cq value output by qPCR and the dilution in each well. Wells with vector amounts higher than the initial input value were scored positively (Yes), and wells with amounts lower than the initial input value were scored negatively (No). The Karber method was then used to calculate TCID50 / mL.
[0059] (1) Day 1: HeLaRC32 cells were seeded into 96-well plates 20-24 hours before infection, HeLaRC32 cells in good condition were digested and counted, at a concentration of 1.2 × 10⁻⁶. 4 Cells were seeded at 1.2 × 10⁶ cells / well, i.e., the cells were diluted with complete culture medium (DMEM + 10% FBS) to a concentration of 1.2 × 10⁶ cells / well. 5 Add 100 μl of cell suspension per well to each cell / ml. Place the cultured cells in a CO2 incubator and continue culturing.
[0060] (2) Day 2: HeLaRC32 cell viral infection a) Reagent preparation: Incubate the culture medium in a 37°C water bath for 20 min, and thaw Ad5 on ice; b) Dilute Ad5 to 2 × 10⁻⁶ with culture medium. 8 / ml for later use; c) Dilution of the test virus: Dilute the test virus to 1.0 × 10⁻⁶ according to its physical titer. 12 After reaching 1.0 × 10⁶ ml, perform serial dilutions to a final concentration of 1.0 × 10⁶ ml. 11 / ml for later use.
[0061] d) Cellular viral infection: Discard the cell supernatant and add 50 μl of the appropriate dilution of the test virus to infect the cells. Infect the cells with 5 dilutions and 1 Ad5 group for each virus, and infect 8 wells for each dilution. The virus in this batch is 1.0 × 10⁻⁶. 6 / ml to 1.0×10 10 Infect the animals at a concentration of / ml, and then incubate them in a CO2 incubator. (3) Day 5: qPCR detection a) Cell lysis and DNA extraction: Add 80 μl of 0.2% Triton X-100 to each well, mix thoroughly by pipetting at least 10 times, and then treat at 37°C for 2 h. b) Collect DNA samples: After incubation, transfer 45 μl of lysis buffer from each well to a new PCR plate; c) Proteinase K treatment: Add 5 μl of 10 mg / mL proteinase K working solution to each well in b), mix well, and then process according to the following procedure: After treatment, store the samples at 4℃ for later use as qPCR reaction templates; • 50°C for 1 hour • 95°C for 20 min Store at 12°C d) Standard configuration: The standard is a linearized plasmid DNA containing the AAV standard reference genome. The standard is serially diluted to obtain a dilution of 2 × 10⁻⁶. 6 Up to 2×10 1 ds copies / μl of the standard curve are available for use.
[0062] e) qPCR detection: The reaction system and reaction program are shown in Table 13 and Table 14, respectively, and are set as follows: the template loading amount is 1 μl; after 2 h, 50 μl of fresh culture medium is added to the experimental wells and the wells are placed in a CO2 incubator for further incubation.
[0063] Table 13. qPCR reaction system
[0064] Table 14. qPCR reaction conditions
[0065] (4) Results Analysis: a) Calculate the initial number of vector copies added to each well based on the physical titer of the virus to be tested, the volume of virus added to the 96-well plate, and the dilution. b) Multiply the vector copy number detected by qPCR by the dilution factor 160 to get the total number of vector copies in the target well. Subtract the initial vector copy number from a) to get the copy number generated by amplification after infection. Calculate the copy value for each well. c) Determining the positive wells for each dilution: For this assay, the limit of detection for qPCR was set at 20 vector copies. Multiplying this by the dilution factor of 160 gives 3200 vector copies. Therefore, in b), copy values <3200 are considered background, i.e., negative wells, while values >3200 are positive wells.
[0066] d) The Spearman-Karber method was used to calculate the TCID50 / mL of the virus to be tested. The infectivity is shown in Table 15. Table 15. Infectivity
[0067] Experimental results showed no significant difference in the infectivity of AAV9 packaged by the old and new RepCap.
[0068] Example 5: Capsule ID Detection Different serotypes of viruses contain different coat proteins. Differential scanning fluorescence (DSF) utilizes the process of heating the sample on a qPCR instrument. As the temperature increases, the protein surface denatures, and the fluorescent dye SYPRO™ Orange binds to the exposed hydrophobic groups until the protein is fully expanded, reaching its maximum fluorescence signal. Subsequently, the fluorescence signal decreases due to thermal quenching and / or protein aggregation. Therefore, the temperature at which the fluorescence signal changes is considered the corresponding transition temperature (T0). m Each serotype's viral outer shell has a specific T... m Therefore, differential scanning fluorescence can be used to identify the capsid ID of AAV virus.
[0069] (1) Virus and dye preparation (to be performed in Viral BSC) a) Virus treatment: Remove the virus and thaw it on ice. Vortex thoroughly for 30 seconds, centrifuge at 3000 rpm for 10 seconds, and place on ice until used. If the sample titer is greater than 1E+13GC / mL, dilute the sample with PBS to 1E+13GC / mL first. If the titer is less than 1E+13GC / mL, no dilution is required and the sample can be loaded directly. b) Dye dilution: Take out SYPRO™ Orange dye (stock solution is 5000×), and dilute it 100 times with PBS to 50×; (2) qPCR reaction setup a) In the BSC, add the test solution and sample sequentially to the qPCR 96-well plate according to Table 16. Table 16. qPCR reaction system
[0070] Note: When the sample titer is 1E+13 GC / mL, the loading volume is 10 μL; when the sample titer is less than 1E+13 GC / mL, the loading volume is 15 μL. NC consists of 2 μL 50 × SYPRO™ Orange dye + 18 μL PBS.
[0071] b) Seal the plate with the added samples using quantitative PCR sealing film, vortex, and centrifuge on a microplate centrifuge.
[0072] (3) qPCR detection a) Program design: Click File→New→Protocol, change Sample Volume to 20 μL, select Insert Melt Curve for qPCR reaction program, set the temperature to 45℃-90℃, hold for 2 min, and increase the temperature by 0.4℃.
[0073] b) Plate layout: Click Next → Create New Plate, hold down the left mouse button to select all sample areas, click User Preferences, set Plate Type to BR White, and check the Cal Gold540 option in Fluorophores.
[0074] c) Data Export: Select Negative for Peak Type, export the data to Excel, and perform result analysis.
[0075] (4) Data analysis is shown in Tables 17 and 18: Table 17. Capsid ID T of different serotypes m Value reference range
[0076] Table 18. Data from this test
[0077] All experimental results were within the reference range, and the T values of the two RepCap plasmids packaging viruses were within the reference range. m This consistency further demonstrates that the newly designed pRH85-Cap921 has no impact on the physical properties of the virus.
[0078] Example 6: Effects on other serotypes To test the effect of the pRH85-Cap921 plasmid structure on the yield of other AAV serotypes, we replaced Cap9 in pRH85-Cap921 with Cap2 and Cap8 respectively to form pRH85-Cap201 and pRH85-Cap801. The pRH85-Cap201 and pRH85-Cap801 plasmids were constructed according to the method described in Example 1. Virus preparation was performed according to the method described in Example 2, and production and purification were carried out according to the method described in Example 3. The yields of AAV2 and AAV8 were tested according to the AAV9 yield testing methods described in Examples 4 and 5. Statistical results are shown in […]. Figure 4 As can be seen, the newly designed plasmid structure packaged viruses AAV2-100-042GK (pRH85-Cap201) and AV8-100-042GK (pRH85-Cap801) both have higher yields than commonly available plasmid viruses. Therefore, our new plasmid structure is also applicable to other serotypes. Thus, we have invented a structure for AAV packaging plasmids that can improve the yield of all AAV serotypes without affecting virus quality.
[0079] By incorporating via reference The full contents of every patent and scientific document mentioned in this article are incorporated herein by reference for all purposes.
[0080] Equivalence This disclosure may be embodied in other specific ways without departing from its spirit or essential characteristics. Therefore, the above embodiments should be considered illustrative in all cases and not as limiting of the invention described herein. Consequently, the scope of this disclosure is defined by the appended claims rather than by the foregoing description and is intended to be encompassed therein by all variations within the equivalent meaning and scope of the claims.
Claims
1. A nucleic acid sequence, comprising a first sequence, a second sequence and a third sequence from the 5' end to the 3' end, wherein the first sequence is as shown in SEQ ID NO: 13, the second sequence is as shown in SEQ ID NO: 15, and the third sequence is as shown in SEQ ID NO:
17.
2. The nucleic acid sequence according to claim 1, wherein the nucleic acid sequence is shown in SEQ ID NO:
18.
3. The nucleic acid sequence of claim 1, wherein the first sequence, the second sequence and the third sequence are directly connected or connected by a connecting sequence.
4. Use of the nucleic acid sequence according to any one of claims 1 to 3 in enhancing the expression of a Cap gene.
5. The use according to claim 4, wherein the Cap gene serotype is selected from AAV9, 8, 1, 2, 3, 3B, 4, 5, 6, 7, 10, 11, 12, 13, rh10 or hu37.
6. A recombinant adeno-associated virus packaging plasmid, characterized in that: The recombinant adeno-associated virus packaging plasmid comprises a Rep gene and a Cap gene, wherein the 5' end of the Cap gene comprises the nucleic acid sequence of any one of claims 1 to 3.
7. The recombinant adeno-associated virus packaging plasmid according to claim 6, wherein the nucleic acid sequence of the recombinant adeno-associated virus packaging plasmid is shown in any one of SEQ ID NOs: 2-4.
8. A recombinant adeno-associated virus vector system, characterized in that: It comprises the recombinant adeno-associated virus packaging plasmid, the recombinant adeno-associated virus core plasmid and the recombinant adeno-associated virus element helper plasmid as described in claim 6 or 7.
9. A recombinant adeno-associated virus particle, characterized in that: The method is obtained by co-transfecting a packaging cell line with the recombinant adeno-associated virus packaging plasmid, the recombinant adeno-associated virus core plasmid and the recombinant adeno-associated virus element helper plasmid as described in claim 6 or 7.
10. Use of the recombinant adeno-associated virus packaging plasmid according to claim 6 or 7 in preparing a recombinant adeno-associated virus.
Citation Information
Patent Citations
Preparation and use of truncated Cap protein of porcine circovirus type 2
CN101948849A
Novel AAV8 mutant capsids and compositions containing same
CN109661470A
Construction of stable cell line carrying orthogonal tRNA / aminoacyl tRNA synthetases
CN112725282A
Recombinant adeno-associated virus packaging plasmid, mutant as well as preparation method and application of recombinant adeno-associated virus packaging plasmid
CN117230117A
Packaging plasmid for reducing rcAAV (recombinant adeno-associated virus) residue in recombinant adeno-associated virus and application
CN117660533A
